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Bonediseaseinpatients withjuvenileidiopathicarthritis(JIA)isassociatedwithfocal(jointerosionandjuxtaarticularosteopenia)
and systemic bone loss (generalized osteopenia or reduction of bone mass density). Pathophysiology of bone loss is multifactorial
and involves particularly proinﬂammatory cytokines and deleterious eﬀects of glucocorticoid therapy. Clinical studies in patients
withJIAindicate excessive activationofosteoclastogenesisandreduction ofboneformation.Reduction ofphysicalactivity, muscle
atrophy caused by high disease activity, and compulsory restriction in movements are also associated with bone loss. In patients
with JIA, the disease can be complicated by growth cartilage involvement and systemic or local growth retardation. In the absence
of preventive measures, fragility fractures can occur even at an early age.
1.Introduction
Juvenile idiopathic arthritis (JIA) is a systemic autoimmune
chronic inﬂammatory joint disease beginning until 16 years
of age. JIA is the most frequent rheumatic systemic disease
in the childhood. In the industrial countries, the incidence
of JIA is 5–18 and prevalence of JIA is 30–150/100000
childrenuntil 16 years old.In the Czech Republic,the annual
incidence of JIA is 13/100 000 and prevalence of JIA is
140/100000 children until 16 years old [1]. The initial cause
of the chronic inﬂammatory processes targeting the synovial
lining of joints is not known. Many of the proinﬂammatory
factors stimulate the diﬀerentiation of osteoclasts from the
hematopoieticprecursor.Generalizedbonelossofbonemass
is a common feature in JIA.
2.LowBone Massand Increased
RiskofFracture
During childhood and adolescence in patients with JIA,
when the peak of bone mass is attained in the healthy
people, the accrual of bone mass is suppressed through
direct andindirect mechanisms, namelybytheinﬂammatory
disease, by drug therapy and immobilization [2, 3]. In JIA,
both synovial-derived and soluble cytokines are involved.
Osteopenia or osteoporosis occurs in all of the JIA forms,
most typically in systemic and polyarticular forms ofdisease.
The low bone mass is associated with the high activity of
the disease and with the number of involved joints in JIA
patients [4–9], also with the reduction of bone formation
[4, 6]. Reduced bone mineral density (BMD) is observed at
all sites of the skeleton in the children and adolescents with
JIA and also in adults with JIA. In the cross-sectional study,
the low BMD in lumber spine and hip was found in 40–52%
adultpatientswithJIA[10].However,eventhefullremission
of the disease in young adults is not able to completely
normalize BMD at all skeletal sites. In 229 young adults with
a past history of JIA, persistently low BMD was observed at
the femoral neck and on total body [11]. In another study,
41% of adults with a history of JIA had osteopenia [12].
Therapy with glucocorticoidscan prevent the acquisition
of an optimal peak bone mass in young patients. The lower2 Journal of Osteoporosis
peak of bone mass is associated with the increased risk of
osteoporosis and the increased risk of fracture in the adult
age [13–15].
Drug therapy with glucocorticoids may increase the risk
ofdevelopingosteopeniaandosteoporosis.Vertebralcollapse
is more common in children receiving a cumulative dose of
at least 5g of prednisone equivalents, prolonged periods of
bed rest, and with low BMD and low serum concentrations
of 25-hydroxyvitamin D [13, 16]. In a study in 103 patients
with JIA, 23% had at least one fracture in the presence of
growth failure, articular erosions and high cumulative dose
ofglucocorticoids;56% of these fractures were vertebral [17]
(Figure 1).
3.FracturesandLowLeanMass
The increased risk of fracture has been proven especially in
patients with erosive arthritis, growth retardation and high
cumulative dose of glucocorticoids [2, 3].
Myopathy caused by the autoimmune inﬂammation is
one of reasons of the low lean mass in patients with JIA.
Proinﬂammatory cytokines (especially TNF-α)s t i m u l a t e
protein degradation, inhibit myocyte diﬀerentiation, and
cause myocyte apoptosis [18, 19], as demonstrated by the
muscle biopsies [20]. Glucocorticoid myopathy can also
induce a low lean mass [21]. Patients with JIA are less physi-
cally active than healthy population, their physical condition
is impaired, and risk of fracture is increased [22, 23].
In patients with JIA, there is an important relationship
between risk of fracture, bone mineral density and quantity
of lean mass. The lean mass corelates with BMD at the
various skeletal sites. Bone status in children with JIA (and
also in healthy children) markedly depends on the muscle
force aﬀecting the skeleton [4, 18]. Reduction of whole body
lean mass and higher accrual of fat mass was established
at the early phase of the disease [8]. The increased risk of
forearm fracture was demonstrated also in healthy children
and adolescents with low whole body lean mass and high fat
mass [24]. BMD at the cortical and trabecular bone of the
forearm and bone and lean muscle geometry was measured
in 57 children with JIA using the peripheral quantitative
computed tomography (QCT) [18]. Patients with JIA had
signiﬁcantly reduced cross-sectional area of the lean muscle
mass (CSA). This reduction notably corelated with lean
mucle force and bone geometry abnormalities and with
signiﬁcant reduction of the cortical bone thickness. All of
these can be associated with increased risk of fracture. The
peripheral QCT was also used to demonstrate a reduced calf
lean muscle mass and tibial trabecular BMD and cortical
thickness in patients with JIA [25].
4.GrowthRetardation
The important diﬀerence between JIA and rheumatoid
arthritis in adults lies in growth retardation of children
with JIA, deceleration of growth rate, low stature in adult
age and local growth retardation at sites of joints involved
in arthritis [2, 3]. A signiﬁcantly low stature (the ﬁnal
height below −2 standard deviation, SD) was demonstrated
(a) (b)
Figure 1:Multiple compressivevertebral fractures andrib fractures
in a 22-year-old women diagnosed with JIA at 3years of age. Bone
densitometry (DXA, GE Prodigy): total femurBMDof0,453g/cm2,
T-score −4,5; femur neck BMD of 0,536g/cm2,T - s c o r e−4,2.
in 11% of children with JIA, and in 41% children with
systemic form of disease [26]. Sources of growth retardation
in JIA are multifactorial; chronic inﬂammation and long-
term glucocorticoid treatment are the most relevant. The
linear growth can be improved with remission of the disease.
The growth hormone (GH) and insulin-like growth fac-
tor I (IGF-I) are the most important regulators of postnatal
growth. In children with JIA and serious growth retardation,
the normal pulsative secretion of growth hormone, but low
levels of IGF-I were described (resistance to growth hor-
mone). Proinﬂammatory cytokines inﬂuence linear growth
of children by their systemic eﬀects and by local eﬀects on
growth cartilage of long bones [26]. Increased production of
interleukin6(IL-6)andinterleukin1beta(IL-1β) accelerates
degradation of insulin-like growth factor I binding protein 3
(IGFBP-3) resulting in reduction of IGF-I levels and growth
retardation. Chondrocyte apoptosis induced by the tumor
necrosisfactorα(TNFα)throughthemediumFas-associated
death domain (FADD) acts the important part in growth
abnormalities [26]. Growth retardation caused by chronic
inﬂammation and glucocorticoidtreatment can be positively
inﬂuenced by growth hormone treatment [27].
5.Biochemical Markersof Bone Turnover
Studies of bone formation and bone resorption markers
are not unambiguous; however, most studies indicated
prevalence of bone resorption over bone formation [5],Journal of Osteoporosis 3
the others conversely indicate reduction of the bone for-
mation [4, 6, 28]. Decreased bone formation in the course
of adolescent growth spurt obstructs achievement of peak
of bone mass and increase risk of fracture in the adult age
[4, 13, 14]. Successful treatment of the disease is associated
with elevation of bone formation markers [6].
In prepubertal children with active JIA, prevalence of
bone resorption markers over reduced markers of bone
formation corelated with laboratory indices of disease activ-
ity, namely in children with polyarticular phase of JIA [4,
6, 28, 29]. Except for the high disease activity, reduced
concentrations of bone turnover markers and low BMD
were found in patients with joint destruction and longer
disease duration [29]. According to Pereira et al., bone
formation in patients with JIA was suppressed from early to
middle puberty, while at older patients with JIA, the main
factor of bone loss was the elevation of bone resorption
[30]. Thus, similarly to adults with rheumatoid arthritis,
the proinﬂammatory cytokines (TNF-α, IL-1) produced
by synovial membrane are responsible for excessive bone
resorption also in adult patients with JIA [31].
6.Cellularand MolecularMechanisms of
Bone RemodelinginPatientswithJIA
6.1. Inﬂuence of Proinﬂammatory Cytokines on Bone Remod-
eling. Proinﬂammatory cytokines, such as tumor necrosis
factor α (TNFα), interleukin 1 (IL-1), interleukin 6 (IL-6)
a interleukin 17 (IL-17), present in arthritic joint can cause
an excessive osteoclastogenesis [32–35]. TNFα signiﬁcantly
elevates bone resorption [36] and attenuates osteoblasto-
genesis and bone formation [37–40]. IL-1 also accelerates
osteoclast maturation [41]. In patients with rheumatoid
arthritis, treatment with TNFα antibodies demonstrably
reduces joint erosions [32]. IL-17, which is produced by
T-lymfocytes [34, 42, 43] induces osteoclast diﬀerentiation
by increasing expression of RANKL and RANK. On the
contrary, IL-17 suppresses expression of osteoprotegerin in
osteoblasts resulting in prevalence of bone resorption over
bone formation and bone loss [6, 34, 44–46].
6.2. RANKL/RANK/OPG Triad in Patients with JIA. Recep-
tor activator nuclear factor kappa B (RANK) and its ligand
(´ RANKL) have essential importance for osteoclastogenesis
and osteoclast function [47–50]. Osteoprotegerin (OPG) is a
soluble decoy receptor for RANKL produced by osteoblasts.
OPG binding to RANKL prevents RANKL activation of
RANK and thus activation of the osteoclastogenesis [48,
51]. High RANKL/OPG ratio results in prevalence of bone
resorption over bone formation [52].
Increased production of RANKL in synovial ﬂuid and
increased concentrations ofR A N K Li ns e r u ma r ef o u n d
in adults with rheumatoid arthritis [53]. An increased
RANKL/OPG ratio was observed in children with juvenile
dermatomyositis, and in patients with juvenile idiopathic
arthritis [54, 55]. In the later study in patients with JIA,
increased serum OPG concentrations were not suﬃcient to
compensate for increased levels of RANKL [54, 55]. Serum
concentrations of RANKL were increased in all the forms of
JIA [55]. An increased RANKL/OPG ratio was also found in
a subset of 30 girls with polyarticular course of highly active
JIA and joint erosions [56], and in synovia in patients with
polyarticular and enthesitis-related forms of JIA [57].
6.3. Wingless Proteins (Wnt) Signalling Pathway. The extent
of the bone involvement in the rheumatic inﬂammatory
processes depended on age and bone maturity [34]. In
children with JIA, decreased osteoblastic formation and
function may contribute to the bone loss [30, 34, 58, 59].
With this respect, the proinﬂammatory cytokines (especially
TNFα), stimulate production of inhibitors of the Wnt pro-
teins signalling pathway, especially sclerostin and Dickkopf1
(DKK-1) and consequently inhibit osteoblast diﬀerentiation
[60–63]( Figure 1).
The Wnt proteins are large family of factors that bind
to cell-surface receptors of the Frizzled family, causing the
receptors to activate Dishevelled family proteins and ulti-
mately resulting in a change in the amount of β-catenin that
reaches the nucleus and interacts with T-cell factor/lymhoid
enhancer factor (TCF/LEF) family transcription factors to
promotespeciﬁcgeneexpression[64].Decreasedproduction
of DKK-1, an inhibitor of the Wnt signaling pathway, is
associated with reverse of osteoresorptive pattern in mouse
model of rheumatoid arthritis to pattern of osteoarthritis
with increased bone formation and osteophyte formation
[61]. The DKK-1 blockade is associated with stimulation
of OPG production by osteoblasts and consequent decrease
in bone resorption [61, 64]. The importance of Wnt
proteins for susceptibility to JIA was conﬁrmed in the study
of Wnt-1 inducible signaling pathway protein 3 (WISP3)
polymorphism [65].
6.4. Matrix Metalloproteinases and Their Inhibitors in Patients
withJIA. Matrixmetalloproteinases (MMPs)areresponsible
for cartilage destruction and periarticular bone erosions in
juvenile idiopathic arthritis [21, 55, 66–68]. MMP1/tissue
inhibitor of metalloproteinases 1 (TIMP1) and MMP3/
TIMP1 ratios are signiﬁcantly higher in all the forms of JIA
in comparison to healthy controls. These ratios signiﬁcantly
correlate with disease activity and could be eﬃcacious
biomarkers for monitoring of disease development [55].
7. Effectsof Glucocorticoids,and Disease-
Modifying AntirheumaticDrugs(DMARDs)
In children, a negative correlation between bone mass and
cumulative dose of glucocorticoids was found [69–71].
During the childhood and adolescence, glucocorticoids can
impair physiological process of bone mass accumulation and
can cause deterioration of peak of bone mass resulting in
increased risk of fracture in future life.
Methotrexate, which is the most frequent DMARDs in
children, can cause osteopenia in children patients with
malignancies, but low-dose methotrexate used in inﬂam-
matory diseases did not inﬂuence negatively the bone mass
[72, 73].4 Journal of Osteoporosis
8.TherapeuticOptionsto Improve Bone
StatusinJIA
8.1. TNFα Antibodies Treatments. Biological treatment with
inﬂiximab and etanercept in children with JIA is associated
with decrease in disease activity [74–76]. The positive
inﬂuence of treatment with TNFα antibodies was also
documented upon the skeleton. Simonini was the ﬁrst to
demostrate increased bone mass after 1-year etanercept
treatment in children with JIA; reduction of bone loss was
associated with therapeutic response with decreased disease
activity [75]. Etanercept also improves the linear growth in
children with JIA [76].
8.2. Antiresorption Treatments. Aminobisphosphonates rep-
resent an eﬀective option in patients with documented
prevalence of bone resorption over bone formation [77].
In JIA, calcium and vitamin D, calcitonin, and aminobis-
phosphonates have been studied [78–80]. However, studies
treated small numbers of patients with diﬀerent charac-
teristics of JIA, and controlled studies on both preventive
strategies and treatment in augmenting bone mass and
reducing the fracture risk are still lacking.
8.3. Bone Anabolic Treatments. Growth hormone was eﬀec-
tive in stimulating collagen production and improving
liner growth in JIA [81–83]. However, long-term controlled
studies are needed to determine impact on bone mass and
boneturnoverandtherisksofgrowthhormonetherapy[84].
In adult patients with closed linear growth and severe
osteoporosis, an intermittent administration of PTH 1–34
(teriparatide) or PTH 1–84 represents an eﬀective option to
restore bone structure that has previously been lost [85].
9.Conclusion
Well-timed and eﬃcient treatment of JIA in children and
adolescents can improve bone status. However, patients who
suﬀered from JIA during childhood and adolescence may
attain decreased bone mass and have an increased risk of
fragilityfractures. Itis important toidentify thesubjects with
an increased risk of fracture as early as possible. In adult
patients with closed linear growth, it is necessary not only to
reduceboneresorption,butalsotosupportformationofnew
healthy bone mass. Several new therapeutical procedures are
under investigation.
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